Overview

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is an Open-Label, Multicenter, Dose Escalation, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.